Fig. 2: Blood pressure changes after rostafuroxin or losartan treatment in carriers of the profile P2a or of LSS AA or CC genotypes. | The Pharmacogenomics Journal

Fig. 2: Blood pressure changes after rostafuroxin or losartan treatment in carriers of the profile P2a or of LSS AA or CC genotypes.

From: Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan

Fig. 2

A Time-course of mean OSBP changes (mmHg) at visit 1, at baseline, and visits 4 (2 weeks), 5 (4–5 weeks), and 6 (9 weeks) in profile P2a in the four treatments groups. Data are means ± SE. B OSBP and ODBP fall (mmHg) in LSS AA and CC carriers treated with 50 mg losartan or 50 µg rostafuroxin. ANCOVA test. Data adjusted for baseline are means (±SE). ∆ = delta OSBP or ODBP. Numbers in the columns refer to each subgroup sample size. * ∆ = 13.4 mmHg OSBP for LSS AA, 50 mg losartan vs 50 µg rostafuroxin, P = 0.031; ** LSS x treatment (OSBP), P = 0.023; *** ∆=9.1 mmHg ODBP for LSS AA, 50 mg losartan vs 50 µg rostafuroxin, P = 0.095; **** LSS x treatment (ODBP), P = 0.013. C OSBP fall (mmHg) in LSS AA and CC individual carriers treated with 50 µg rostafuroxin, in PEARL-HT and OASIS-HT trials. The values below the histograms are the OSBP levels reached by the individual patients at the end of the treatment period.

Back to article page